Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 13
1989 6
1990 4
1991 17
1992 9
1993 32
1994 22
1995 25
1996 24
1997 31
1998 48
1999 36
2000 40
2001 46
2002 48
2003 58
2004 41
2005 45
2006 65
2007 67
2008 69
2009 86
2010 74
2011 94
2012 95
2013 103
2014 81
2015 57
2016 56
2017 57
2018 34
2019 43
2020 29
2021 29
2022 29
2023 24
2024 32
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,542 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Yin J, Mei Z, Shi S, Du P, Qin S. Yin J, et al. Arch Gynecol Obstet. 2022 Dec;306(6):1891-1900. doi: 10.1007/s00404-022-06504-5. Epub 2022 Mar 19. Arch Gynecol Obstet. 2022. PMID: 35305140 Review.
BACKGROUND: There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregnancy. OBJECTIVE: To compare antihypertensive efficacy, pregnancy outcome and safety of amlodipine with nifedipine on hypertension duri …
BACKGROUND: There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregna …
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Jin X, Kim MH, Han KH, Hong SJ, Ahn JC, Sung JH, Cho JM, Lee HC, Choi SY, Lee K, Kim WS, Rhee MY, Kim JH, Hong SP, Yoo BS, Cho EJ, Lee JH, Kim PJ, Park CG, Hyon MS, Shin JH, Lee SH, Sung KC, Hwang J, Kwon K, Chae IH, Seo JS, Kim H, Lee H, Cho Y, Kim HS. Jin X, et al. J Clin Hypertens (Greenwich). 2020 Oct;22(10):1835-1845. doi: 10.1111/jch.13893. Epub 2020 Sep 16. J Clin Hypertens (Greenwich). 2020. PMID: 32937023 Free PMC article. Clinical Trial.
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 mg, telmisartan 80 mg + rosuvastatin 20 mg, and telmisartan/amlodipine 80/5 mg. ...The LS Mean for the percent changes from baseline …
We enrolled 202 patients who were randomly divided into the following three groups: telmisartan/amlodipine 80/5 mg + rosuvastatin 20 …
Amlodipine as adjuvant therapy to current chelating agents for reducing iron overload in thalassaemia major: a systematic review, meta-analysis and simulation of future studies.
Elfaituri MK, Ghozy S, Ebied A, Morra ME, Hassan OG, Alhusseiny A, Abbas AS, Sherif NA, Fernandes JL, Huy NT. Elfaituri MK, et al. Vox Sang. 2021 Sep;116(8):887-897. doi: 10.1111/vox.13083. Epub 2021 Feb 26. Vox Sang. 2021. PMID: 33634883
Therefore, previous research has recommended amlodipine as an auxiliary treatment to current chelating agents for reducing iron overload in thalassaemia patients. ...Similarly, there was insignificant difference in cardiac T2* between amlodipine and control groups { …
Therefore, previous research has recommended amlodipine as an auxiliary treatment to current chelating agents for reducing iron overl …
Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee DE, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr, Lakshman P, Uluwattage W, Hay P, Pereira T, Amarasena N, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Gnanenthiran SR, Whelton PK; GMRx2 Investigators. Rodgers A, et al. Lancet. 2024 Oct 19;404(10462):1536-1546. doi: 10.1016/S0140-6736(24)01744-6. Lancet. 2024. PMID: 39426836 Clinical Trial.
In a 4-week active run-in, existing medications were switched to GMRx2 half dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg). Participants were then randomly allocated (2:1:1:1) to continued GMRx2 half dose or to each possible dual combination of compone …
In a 4-week active run-in, existing medications were switched to GMRx2 half dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamid …
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open-Label, Noninferiority Study (PARASOL Study).
Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, Nozato Y, Kario K, Rakugi H. Yamamoto K, et al. J Clin Hypertens (Greenwich). 2025 Jan;27(1):e14938. doi: 10.1111/jch.14938. Epub 2024 Dec 4. J Clin Hypertens (Greenwich). 2025. PMID: 39632589 Free PMC article. Clinical Trial.
In this open-label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blo …
In this open-label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one …
Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis.
Gao Y, Zhou D, Yang P. Gao Y, et al. Ann Palliat Med. 2021 Oct;10(10):10768-10778. doi: 10.21037/apm-21-2455. Ann Palliat Med. 2021. PMID: 34763438 Free article.
Amlodipine treatment also significantly reduced the LV mass index. The mean difference (MD) between the follow-up and baseline LV mass index was -12.9; 95% CI: -15.4 to -10.4 (P<0.001). ...There was no significant decrease in the LV end-diastolic diameter following a …
Amlodipine treatment also significantly reduced the LV mass index. The mean difference (MD) between the follow-up and baseline LV mas …
Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis.
Luo Y, Ren L, Jiang M, Chu Y. Luo Y, et al. Rev Cardiovasc Med. 2019 Jun 30;20(2):91-98. doi: 10.31083/j.rcm.2019.02.31814. Rev Cardiovasc Med. 2019. PMID: 31345001 Free article.

Administration of amlodipine in the evening could significantly reduce the nighttime blood pressure (RR = 2.04, 95% CI 1.27-2.81, P < 0.00001), increased non-dipper alteration (RR = 0.51, 95% CI 0.41-0.63, P < 0.00001), and contained better anti-hypertension efficacy

…
Administration of amlodipine in the evening could significantly reduce the nighttime blood pressure (RR = 2.04, 95% CI 1.27-2.81, P & …
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis.
Pal D, Maji S, Maiti R. Pal D, et al. High Blood Press Cardiovasc Prev. 2023 Sep;30(5):401-410. doi: 10.1007/s40292-023-00601-5. Epub 2023 Sep 28. High Blood Press Cardiovasc Prev. 2023. PMID: 37768510 Review.
Some studies have found that the blood pressure-lowering effect of azelnidipine is more than amlodipine, and others found the effect similar. AIM: This meta-analysis was conducted to evaluate the efficacy of azelnidipine in managing hypertensive patients by lowering Systol …
Some studies have found that the blood pressure-lowering effect of azelnidipine is more than amlodipine, and others found the effect …
Amlodipine: Can act as an antioxidant in patients with transfusion-dependent beta-thalassemia? A double-blind, controlled, crossover trial.
Darvishi-Khezri H, Khalilzadeh Arjmandi H, Aliasgharian A, Shaki F, Zahedi M, Kosaryan M, Karami H, Naeimayi Aali R, Salehifar E. Darvishi-Khezri H, et al. J Clin Lab Anal. 2022 Dec;36(12):e24752. doi: 10.1002/jcla.24752. Epub 2022 Nov 10. J Clin Lab Anal. 2022. PMID: 36357338 Free PMC article. Clinical Trial.
BACKGROUND AND AIM: This study aimed to assess the antioxidant effects of amlodipine in transfusion-dependent beta-thalassemia (TDT) patients. METHODS: This crossover trial consisted of two sequences (AP and PA). In the AP sequence, nine cases received amlodipine 5 …
BACKGROUND AND AIM: This study aimed to assess the antioxidant effects of amlodipine in transfusion-dependent beta-thalassemia (TDT) …
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus.
Seki Y, Morimoto S, Kimura S, Takano N, Yamashita K, Bokuda K, Sasaki N, Watanabe D, Ichihara A. Seki Y, et al. Kidney Blood Press Res. 2023;48(1):688-700. doi: 10.1159/000533834. Epub 2023 Oct 20. Kidney Blood Press Res. 2023. PMID: 37866351 Free PMC article. Clinical Trial.
Systolic blood pressure significantly decreased at 12 weeks (-10 mm Hg, p = 0.001) and 24 weeks (-10 mm Hg, p = 0.001) in the amlodipine group and at 24 weeks (-11 mm Hg, p = 0.001) in the aliskiren group. Diastolic blood pressure significantly decreased at 24 weeks (-6 mm …
Systolic blood pressure significantly decreased at 12 weeks (-10 mm Hg, p = 0.001) and 24 weeks (-10 mm Hg, p = 0.001) in the amlodipine …
1,542 results

Searches related to "amlodipine"